Hepatitis C Virus
New findings in hepatitis C virus described from the United States and Taiwan
Published in Virus Weekly, September 5th, 2006
Study 1: A study from the United States has reported on the effect of low dose peginterferon alpha-2b with ribavirin for the initial treatment of chronic hepatitis C.
"A prospective randomized trial was undertaken to test the efficacy of low and standard doses of pegylated interferon alpha-2b in combination with ribavirin for the initial treatment of chronic hepatitis C," wrote E.L. Krawitt and colleagues, University of Vermont.
They continued, "By nature of its design the study also provided data on response to therapy over a spectrum of doses of...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
Source: Virus Weekly (2006-09-05)
More Articles from Virus Weekly
- Dendritic Cell Vaccine
Infection of dendritic cells with vaccinia virus MVA reveals maturation-dependent cytopathogenicity - Influenza B Virus Epidemiology
Victoria lineage influenza B virus re-emerging in Brazil - Measles Virus Evolution
High substitution rate of measles virus may allow evolution of escape - Virology
Liver viral vector treatment produces long-term correction of ammonia metabolism - Virology
Recombinant adenoviral vectors turn on the type I interferon system - Airway Viral Infection
Antiviral defense impaired in epithelial nitric oxide-deficient patients - More from this issue of Virus Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
